Design and optimization of thermosensitive nanoemulsion hydrogel for sustained-release of praziquantel

被引:20
|
作者
Cong, Zhaotong [1 ]
Shi, Yanbin [1 ]
Peng, Xue [1 ]
Wei, Bei [1 ]
Wang, Yu [1 ]
Li, Jincheng [1 ]
Li, Jianyong [2 ]
Li, Jiazhong [1 ]
机构
[1] Lanzhou Univ, Sch Pharm, 199 Donggang West Rd, Lanzhou 730000, Peoples R China
[2] CAAS, Inst Lanzhou Husb & Anim Pharmaceut, Lanzhou, Peoples R China
关键词
Praziquantel; nanoemulsion; hydrogel; Box-Behnken design; cytotoxicity; pharmacokinetics; SCHISTOSOMIASIS-MANSONI; DRUG-DELIVERY; FORMULATION; LIPOSOMES; EFFICACY;
D O I
10.1080/03639045.2016.1270960
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objective: This work aimed to develop an alternative sustained-release thermosensitive praziquantelloaded nanoemulsion (PZQ-NE) hydrogel for better schistosomiasis treatment. Significance: PZQ-NE-dispersed chitosan/glycerol 2-phosphate disodium/HPMC (NE/CS/beta-GP/HMPC) hydrogel was successfully prepared to improve bioavailability of PZQ. Methods: Solubility tests and pseudo-ternary phase diagrams were applied to screen optimal oils, surfactants and co-surfactants of NE. The hydrogels were characterized for gelling time, surface exudates, rheological properties and in vitro drug release. Formulation optimization of NE/CS/beta-GP/HMPC hydrogel was conducted by Box-Behnken experimental design combined with response surface methodology. In vitro cytotoxicity of hydrogel was studied by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide method. The sustained-release property of PZQ in NE and optimized hydrogel was evaluated by pharmacokinetic study in rabbits. Results: The formulation of PZQ-NE consisted of mass ratio of 12.5% capryol 90 containing PZQ (160mg/g), 40% cremophor RH 40/tween 20 and transcutol HP (S/CoS = 2: 1), 47.5% deionized water. PZQ releasing from NE/CS/beta-GP/HMPC hydrogels was best fitted to Higuchi model and governed by diffusion. Rheological investigation evidenced the themosensitive gelation of different hydrogel systems and their gel-like character at 37 degrees C. The optimized hydrogel formulation consisted of HPMC solution (103.69mg/g), 3.03% (w/v) chitosan and 14.1% (w/v) beta-GP showed no cytotoxicity when the addition of NE was no more than 100mg/g. Pharmacokinetic parameters indicated that NE/CS/beta-GP/HMPC hydrogel can significantly slow down drug elimination, prolong mean residence time and improve bioavailability of PZQ. Conclusions: NE/CS/beta-GP/HMPC hydrogel possessed sustained-release property and could be an alternative antischistosomal drug delivery system with improved therapeutic effect.
引用
收藏
页码:558 / 573
页数:16
相关论文
共 50 条
  • [41] INDOMETHACIN SUSTAINED-RELEASE
    GREEN, JA
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1984, 18 (12): : 1004 - 1007
  • [42] SUSTAINED-RELEASE ANTIHISTAMINE
    YOUNG, GC
    PRACTITIONER, 1964, 193 (115) : 664 - &
  • [43] SUSTAINED-RELEASE THEOPHYLLINES
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1984, 26 (652): : 1 - 3
  • [44] SUSTAINED-RELEASE TABLET CONTAINING OXAZEPAM - STUDY AND DESIGN
    FERREIRA, DC
    PRISTA, LV
    MORGADO, RM
    LOBO, JMS
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1995, 21 (05) : 591 - 604
  • [45] AN EXAMPLE OF PHARMACEUTICAL STUDIES ON SUSTAINED-RELEASE DOSAGE DESIGN
    YAMAKAWA, I
    SHIMOMURA, M
    HATTORI, T
    WATANABE, S
    TSUTSUMI, J
    SHINODA, A
    MIYAKE, Y
    JOURNAL OF PHARMACOBIO-DYNAMICS, 1984, 7 (02): : S38 - S38
  • [46] SUSTAINED-RELEASE LEVODOPA
    WOODS, AC
    GLAUBIGER, GA
    CHASE, TN
    LANCET, 1973, 1 (7816): : 1391 - 1391
  • [47] SUSTAINED-RELEASE MORPHINE
    BORODA, C
    ANNALS OF INTERNAL MEDICINE, 1984, 100 (04) : 617 - 617
  • [48] SUSTAINED-RELEASE THEOPHYLLINE
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1981, 23 (23): : 97 - 98
  • [49] SUSTAINED-RELEASE DIHYDROCODEINE
    不详
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 1991, 141 (18-19) : 410 - 410
  • [50] SUSTAINED-RELEASE OF SULFADIAZINE
    WISE, DL
    MCCORMICK, GJ
    WILLET, GP
    ANDERSON, LC
    HOWES, JF
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1978, 30 (11) : 686 - 689